Sign in Subscribe

chemo

A collection of 72 issues

AZUR-4 Phase II trial tests neoadjuvant dostarlimab plus CAPEOX in MSS stage III colon cancer

Skip to content The CRC Digest ◆ TRIAL DATA AZUR-4 Phase II trial tests neoadjuvant dostarlimab plus CAPEOX in MSS stage III colon cancer This randomized Phase II study compares neoadjuvant dostarlimab plus CAPEOX versus CAPEOX alone in previously untreated T4N0 or stage III mismatch repair proficient/microsatellite stable resectable colon

Single-Institution Experience with Cytoreductive Surgery and HIPEC for Colorectal Peritoneal Metastases

Skip to content The CRC Digest ▸ TREATMENT Single-Institution Experience with Cytoreductive Surgery and HIPEC for Colorectal Peritoneal Metastases Retrospective study (2009–2024) evaluated cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy in patients with colorectal peritoneal metastases. (Radiol Oncol) This content is informational only and does not constitute medical advice. Always

Meta-analysis finds conflicting evidence on ctDNA RAS testing for anti-EGFR therapy

Skip to content The CRC Digest ◇ RESEARCH Meta-analysis finds conflicting evidence on ctDNA RAS testing for anti-EGFR therapy A systematic review of patients with tissue RAS wild-type tumors receiving first-line chemotherapy plus anti-EGFR therapy found inconsistent results on whether ctDNA RAS status predicts outcomes, possibly due to differences in assay

COMMIT trial analysis examines chemoimmunotherapy in dMMR metastatic CRC

Skip to content The CRC Digest ◆ TRIAL DATA COMMIT trial analysis examines chemoimmunotherapy in dMMR metastatic CRC A new analysis explores what the COMMIT trial can and cannot tell us about combining chemotherapy with immunotherapy in patients with deficient DNA mismatch repair metastatic colorectal cancer. (Journal of Clinical Oncology) This

Phase 3 ANCHOR trial compares anlotinib to bevacizumab plus chemotherapy in RAS/BRAF wild-type metastatic CRC

Skip to content The CRC Digest ◆ TRIAL DATA Phase 3 ANCHOR trial compares anlotinib to bevacizumab plus chemotherapy in RAS/BRAF wild-type metastatic CRC This multicenter, randomized phase 3 trial evaluated first-line anlotinib versus bevacizumab plus CapeOX in patients with RAS/BRAF wild-type unresectable metastatic colorectal cancer. (Nature via Google

High-dose vitamin D3 does not improve progression-free survival in metastatic colorectal cancer

Skip to content The CRC Digest ◆ TRIAL DATA High-dose vitamin D3 does not improve progression-free survival in metastatic colorectal cancer The phase III SOLARIS trial found median PFS was 11.8 months with high-dose vitamin D3 (8,000 IU then 4,000 IU daily) versus 10.3 months with standard-dose

Oral TKI anlotinib shows non-inferiority to bevacizumab plus chemotherapy in first-line RAS/BRAF wild-type metastatic colorectal cancer

Skip to content The CRC Digest ◆ TRIAL DATA Oral TKI anlotinib shows non-inferiority to bevacizumab plus chemotherapy in first-line RAS/BRAF wild-type metastatic colorectal cancer The phase 3 ANCHOR trial (NCT04854668) compared CapeOX chemotherapy combined with anlotinib versus CapeOX combined with bevacizumab in patients with RAS/BRAF wild-type mCRC, evaluating

Study evaluates potential hearing damage from oxaliplatin in preclinical model

Skip to content The CRC Digest ♥ LIVING WITH CRC Study evaluates potential hearing damage from oxaliplatin in preclinical model Mouse study evaluated potential hearing damage induced by oxaliplatin. (Hearing Research) This content is informational only and does not constitute medical advice. Always consult your oncologist or care team. © 2026 The

NF-κB/Lipocalin 2 pathway may reduce chemoresistance in BRAF-mutant colorectal cancer by promoting ferroptosis

Skip to content The CRC Digest ◇ RESEARCH NF-κB/Lipocalin 2 pathway may reduce chemoresistance in BRAF-mutant colorectal cancer by promoting ferroptosis Preclinical research found that the NF-κB/LCN2 signaling pathway enhances cisplatin sensitivity in BRAF V600E-mutant CRC cells through iron-dependent cell death. (Cancers) This content is informational only and does

Total Neoadjuvant Therapy With Long-Course Radiotherapy Studied in High-Risk Rectal Cancer

Skip to content The CRC Digest ◆ TRIAL DATA Total Neoadjuvant Therapy With Long-Course Radiotherapy Studied in High-Risk Rectal Cancer The multicenter phase III TNTCRT trial compared total neoadjuvant therapy using long-course radiotherapy versus chemoradiotherapy in patients with high-risk locally advanced rectal cancer. (Journal of Clinical Oncology) This content is informational